Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications

Wu, Siyu; Li, Rong; Jiang, Yuan‐Hong; Yu, Jiazheng; Zheng, Jianyi; Li, Zeyu; Li, Mingyang; Xin, Kerong; Wang, Yan; Xu, Zhihao; Li, Shijie; Chen, Xiaonan

doi:10.1016/j.biopha.2023.115027

Cited by 7 publications

(6 citation statements)

References 341 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, urinary biomarkers show promise in urological cancers like bladder and prostate cancer, serving as noninvasive indicators of tumor burden and progression. 31 The scope of liquid biopsy also captures the evolving genomic landscape of tumors. It allows for continuous sampling, allowing clinicians to obtain a comprehensive view of cancer cell genetics across different fluidic environments.…”

Section: B Enefits Of LI Qu Id B I Opsy Across Flu Idsmentioning

confidence: 99%

See 1 more Smart Citation

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Bao,

Zhang,

Guo

et al. 2024

Cancer Science

View full text Add to dashboard Cite

Liquid biopsy is emerging as a pivotal tool in precision oncology, offering a noninvasive and comprehensive approach to cancer diagnostics and management. By harnessing biofluids such as blood, urine, saliva, cerebrospinal fluid, and pleural effusions, this technique profiles key biomarkers including circulating tumor DNA, circulating tumor cells, microRNAs, and extracellular vesicles. This review discusses the extended scope of liquid biopsy, highlighting its indispensable role in enhancing patient outcomes through early detection, continuous monitoring, and tailored therapy. While the advantages are notable, we also address the challenges, emphasizing the necessity for precision, cost‐effectiveness, and standardized methodologies in its broader application. The future trajectory of liquid biopsy is set to expand its reach in personalized medicine, fueled by technological advancements and collaborative research.

show abstract

Section: B Enefits Of LI Qu Id B I Opsy Across Flu Idsmentioning

confidence: 99%

“…For example, urinary biomarkers show promise in urological cancers like bladder and prostate cancer, serving as noninvasive indicators of tumor burden and progression. 31 …”

Section: Benefits Of Liquid Biopsy Across Fluidsmentioning

confidence: 99%

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Bao,

Zhang,

Guo

et al. 2024

Cancer Science

View full text Add to dashboard Cite

show abstract

“…Hier sind derzeit jedoch vielversprechende neue Entwicklungen zu erwarten. Insbesondere molekularbiologischen Methoden der "Liquid biopsy" werden ein enormes Potenzial für verschiedene Aspekte der Onkologie, von der Frühdiagnose über die Therapieüberwachung bis hin zur Vorhersage der Prognose zugemessen [76,77].…”

Section: Nicht-urologische Malignome Bei Neurologischen Erkrankungenunclassified

Onkologische Relevanz neurourologischer Erkrankungen

Böthig,

Schöps,

Kowald

et al. 2024

Aktuelle Urol

View full text Add to dashboard Cite

Zusammenfassung Von wenigen Ausnahmen abgesehen ist derzeit die Evidenz wissenschaftlicher Erkenntnisse zur Frage der onkologischen Relevanz neurourologischer Erkrankungen noch gering. Am besten erforscht ist der Zusammenhang zwischen einer langjährigen bestehenden Querschnittlähmung mit ihren Folgen für den unteren Harntrakt und dem Auftreten eines Harnblasenkarzinoms. Diese Karzinome unterscheiden sich vielfältig von Harnblasenkarzinomen bei Patienten ohne Querschnittlähmung: Die Patienten sind im Durchschnitt 20 Jahre jünger, die Tumoren sind sehr häufig bereits muskelinvasiv und schlecht differenziert mit einem hohen Anteil an Plattenepithelkarzinomen, die Prognose ist schlecht. Diese Charakteristika treten auch bei querschnittgelähmten Patienten ohne Dauerkatheterableitung der Harnblase auf. Obwohl der pathophysiologische Zusammenhang im Detail noch ungeklärt ist, so scheint doch der entscheidende Link zwischen einer Querschnittlähmung und dem Auftreten eines Harnblasenkarzinoms das Vorliegen einer neurogenen Blase zu sein. Pathologische Druckverhältnisse in der Harnblase und häufige Harnwegsinfekte bzw. asymptomatische Bakteriurien infolge der neurogenen Fehlsteuerung der Harnblase könnten die pathophysiologisch entscheidenden Faktoren darstellen. Insofern stellt das Harnblasenkarzinom bei chronisch querschnittgelähmten Patienten einen Modelltumor nach einer Denervierung dar. Die klinisch wichtige Frage eines Screenings erfordert zukünftige interdisziplinäre Forschungsansätze.

show abstract

“…With the pivotal roles in an exchange between renal cells and target cells, EVs are expected to serve as new molecular markers for the detection of kidney diseases, carrying specific molecular substances in source renal cells with the lipid structure to protect the contents from being degraded [48,49]. At present, the study of EVs, especially exosomes, has been involved in the field of liquid biopsy [50,51].…”

Section: Extracellular Vesicles As Biomarkers Of Renal Diseasesmentioning

confidence: 99%

Extracellular Vesicles in Kidney Disease

2024

Extracellular Vesicles - Applications and Therapeutic Potential

View full text Add to dashboard Cite

The kidney is the mainly apparatus in the human body, with a complex organizational structure and diverse pathological changes closely related to other organs. Extracellular vesicles are vesicles with diameters ranging from tens of nanometers to several micrometers, originating from multiple intracellular vesicles or local cell membranes. They carry various information from the source cells and operate between various cells in the kidney and extrarenal organs, conveying substances between cells. They play a large part in signal transmission within the kidney and between the kidney and other organs. Detecting changes in extracellular vesicles and their cargo can monitor both renal neoplastic and nonneoplastic diseases. Extracellular vesicles derived from various stem cells, loaded with bioactive substances, can be applied to some extent to treat kidney diseases. Bioengineering drugs using extracellular vesicles as carriers are also playing an increasingly big role in treating kidney diseases. Research on extracellular vesicles has achieved certain results and has some preclinical applications, but there is still a process for large-scale and widespread application.

show abstract

Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications

Cited by 7 publications

References 341 publications

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine

Onkologische Relevanz neurourologischer Erkrankungen

Extracellular Vesicles in Kidney Disease

Contact Info

Product

Resources

About